risperidone has been researched along with Drug-Related Side Effects and Adverse Reactions in 42 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sertindole and risperidone are effective and well-tolerated in patients with treatment-resistant schizophrenia." | 9.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr." | 7.79 | Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. ( Chaves, KM; de Araújo Júnior, RF; de Araújo, AA; de Paula Soares Rachetti, V; do Socorro Costa Feitosa Alves, M; Filgueira Júnior, A; Guerra, GC; Ribeiro, SB; Serrano-Blanco, A; Soares, LA, 2013) |
| " We hypothesized that a low dose of risperidone in combination with sertraline would reduce serious adverse effects without decreasing treatment response." | 7.30 | Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study. ( Lang, X; Wu, F; Xiu, M; Xue, M; Zang, X; Zhang, X, 2023) |
| "Schizophrenia is a severe disorder that significantly affects the quality of life and total functioning of patients and their caregivers." | 6.50 | Individualizing clozapine and risperidone treatment for schizophrenia patients. ( Assimakopoulos, K; Bartsakoulia, M; Iconomou, G; Mitropoulos, K; Papadima, EM; Patrinos, GP; Squassina, A; Tsermpini, EE, 2014) |
| "Adverse changes in adiposity and insulin sensitivity were observed during 12 weeks of antipsychotic treatment in youths, with the greatest fat increases on olanzapine." | 5.27 | Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial. ( Flavin, KS; Newcomer, JW; Nicol, GE; Patterson, BW; Schechtman, KB; Schweiger, JA; Yingling, MD, 2018) |
| "Sertindole and risperidone are effective and well-tolerated in patients with treatment-resistant schizophrenia." | 5.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| " (2) Articles published between 2004 and 2008 were identified by a PubMed search with the keywords weight gain, metabolic, glucose, insulin, and lipid AND dose combined with amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, and ziprasidone." | 4.85 | Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. ( De Hert, M; Simon, V; van Winkel, R, 2009) |
| "A wide variety of patient groups may benefit from treatment with long-acting risperidone, including patients with suboptimal efficacy, particularly as a result of partial compliance, patients experiencing side-effects with another antipsychotic agent or those with a first episode of schizophrenia." | 4.83 | Clinical experience and management considerations with long-acting risperidone. ( Parellada, E, 2006) |
| "Paliperidone palmitate (PP), a long-acting intramuscular formulation of paliperidone, has been marketed in Europe within the last 10 years and provides an important treatment option for patients with schizophrenia." | 4.02 | Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database. ( Boels, D; Citterio-Quentin, A; Jolliet, P; Mahé, J; Moragny, J; Olry, A, 2021) |
| "This cross-sectional study compared quality of life and side effects in 108 users of olanzapine or risperidone suffering schizophrenia and being attended at psychiatric ambulatory services in Rio Grande do Norte, Brazil." | 3.83 | Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users. ( de Araújo Júnior, RF; de Araújo, AA; Dos Santos, AC; Guerra, GC; Lemos, TM; Medeiros, CA; Ribeiro, SB; Rubio-Valera, M; Serrano-Blanco, A, 2016) |
| "This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr." | 3.79 | Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. ( Chaves, KM; de Araújo Júnior, RF; de Araújo, AA; de Paula Soares Rachetti, V; do Socorro Costa Feitosa Alves, M; Filgueira Júnior, A; Guerra, GC; Ribeiro, SB; Serrano-Blanco, A; Soares, LA, 2013) |
| " We hypothesized that a low dose of risperidone in combination with sertraline would reduce serious adverse effects without decreasing treatment response." | 3.30 | Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study. ( Lang, X; Wu, F; Xiu, M; Xue, M; Zang, X; Zhang, X, 2023) |
| "Genetic variants in pharmacodynamic genes could represent valuable markers of AR risk and antipsychotic safety." | 2.78 | Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. ( Abad-Santos, F; Ayuso, C; Borobia, AM; Cabaleiro, T; Carcas, AJ; López-Rodríguez, R; Novalbos, J; Ochoa, D; Román, M, 2013) |
| " The most common dosage of RLAI used at endpoint was 25 mg every 14 days (60%)." | 2.73 | Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. ( Glue, P; Kissling, W; Medori, R; Simpson, S, 2007) |
| "Preschool children tolerated low-dose risperidone well with no serious adverse effects observed over a 6-month treatment period." | 2.72 | Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. ( Belden, A; Heffelfinger, A; Luby, J; Mrakotsky, C; Spitznagel, E; Stalets, MM; Williams, M, 2006) |
| "Schizophrenia is a severe disorder that significantly affects the quality of life and total functioning of patients and their caregivers." | 2.50 | Individualizing clozapine and risperidone treatment for schizophrenia patients. ( Assimakopoulos, K; Bartsakoulia, M; Iconomou, G; Mitropoulos, K; Papadima, EM; Patrinos, GP; Squassina, A; Tsermpini, EE, 2014) |
| " Although there are some reports in literature, the side effect profile in this population remains poorly defined and there is a need to raise awareness among clinicians across specialties." | 1.91 | Recognising side effects of antipsychotics in children with intellectual disabilities. ( Anand, G; Lee, J; Shepperd, R; Smith, M, 2023) |
| "Retrospective studies using spontaneous reporting system databases have provided a great understanding of adverse drug reactions (ADRs) in the real world, complementing the data obtained from randomized controlled trials." | 1.72 | Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. ( Byeon, SJ; Chung, SJ; Oh, S, 2022) |
| "Lithium carbonate was associated with increased risks of rash (PT), drug interaction (PT), and tubulointerstitial diseases (SMQ)." | 1.72 | Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database. ( Nabekura, T; Uwai, Y, 2022) |
| "Drug-induced weight gain is a profound side effect of numerous commonly used medications." | 1.72 | Drug-induced weight gain in the last 10 years: a descriptive study. ( Ahmed, NJ; Alahmari, A; Almalki, ZS; Alshehri, AM, 2022) |
| "There were significant gaps in adverse effect monitoring in this cohort." | 1.51 | Adherence to Antipsychotic Adverse Effect Monitoring Among a Referred Sample of Children with Intellectual Disabilities. ( Javaheri, KR; McLennan, JD, 2019) |
| " Total dyskinesia score (DyskinesiaS) and total Parkinson score (ParkinsonS) were calculated from the Maryland Psychiatric Research Center Involuntary Movement Scale, total UKU-Cognition score was calculated from the UKU Side Effect Rating Scale." | 1.42 | Neurological Adverse Effects of Antipsychotics in Children and Adolescents. ( Alda, JA; Andrés Nestares, P; Arango, C; Baeza, I; Cantarero, CM; Castro-Fornieles, J; de la Serna, E; Garcia-Amador, M; Merchán-Naranjo, J; Moreno, C; Muñoz, D; Tapia, C, 2015) |
| "Weight gain was found to be lower in the elderly for antipsychotic drugs, in particular for olanzapine." | 1.39 | Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. ( Baumann, P; Greil, W; Grohmann, R; Häberle, A; Schuhmann, T, 2013) |
| " Thus, the aim of this study was to investigate the putative association of genetic markers with the occurrence of four frequently observed adverse events secondary to risperidone treatment: sleepiness, weight gain, extrapyramidal symptoms and sexual adverse events." | 1.39 | Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. ( Abad-Santos, F; Almoguera, B; Ayuso, C; Baca-García, E; Dal-Ré, R; Dorado, P; Fernandez-Piqueras, J; Llerena, A; Lopez-Castroman, J; Riveiro-Alvarez, R; Vaquero-Lorenzo, C, 2013) |
| " There was a dose-response relation for all drugs except quetiapine." | 1.38 | Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. ( Avorn, J; Crystal, S; Gerhard, T; Huybrechts, KF; Levin, R; Lucas, JA; Olfson, M; Schneeweiss, S, 2012) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 8 (19.05) | 29.6817 |
| 2010's | 22 (52.38) | 24.3611 |
| 2020's | 11 (26.19) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Oh, S | 1 |
| Byeon, SJ | 1 |
| Chung, SJ | 1 |
| Eaton, C | 1 |
| Yong, K | 1 |
| Walter, V | 1 |
| Mbizvo, GK | 1 |
| Rhodes, S | 1 |
| Chin, RF | 1 |
| Uwai, Y | 1 |
| Nabekura, T | 1 |
| Ahmed, NJ | 1 |
| Alshehri, AM | 1 |
| Almalki, ZS | 1 |
| Alahmari, A | 1 |
| Lee, J | 1 |
| Shepperd, R | 1 |
| Smith, M | 1 |
| Anand, G | 1 |
| Seifert, J | 1 |
| Maier, HB | 1 |
| Toto, S | 1 |
| Dabbert, D | 1 |
| Lang, X | 1 |
| Xue, M | 1 |
| Zang, X | 1 |
| Wu, F | 1 |
| Xiu, M | 1 |
| Zhang, X | 1 |
| Maruf, AA | 1 |
| Stein, K | 1 |
| Arnold, PD | 1 |
| Aitchison, KJ | 1 |
| Müller, DJ | 1 |
| Bousman, C | 1 |
| Das, A | 1 |
| Boels, D | 1 |
| Mahé, J | 1 |
| Olry, A | 1 |
| Citterio-Quentin, A | 1 |
| Moragny, J | 1 |
| Jolliet, P | 1 |
| Nicol, GE | 2 |
| Ivanov, I | 1 |
| Rafaniello, C | 1 |
| Sessa, M | 1 |
| Bernardi, FF | 1 |
| Pozzi, M | 1 |
| Cheli, S | 1 |
| Cattaneo, D | 1 |
| Baldelli, S | 1 |
| Molteni, M | 1 |
| Bernardini, R | 1 |
| Rossi, F | 1 |
| Clementi, E | 1 |
| Bravaccio, C | 1 |
| Radice, S | 1 |
| Capuano, A | 1 |
| Schoretsanitis, G | 1 |
| Drukker, M | 1 |
| Van Os, J | 1 |
| Schruers, KRJ | 1 |
| Bak, M | 1 |
| Yingling, MD | 1 |
| Flavin, KS | 1 |
| Schweiger, JA | 1 |
| Patterson, BW | 1 |
| Schechtman, KB | 1 |
| Newcomer, JW | 1 |
| Eugene, AR | 2 |
| Eugene, B | 2 |
| Javaheri, KR | 1 |
| McLennan, JD | 1 |
| Downing, L | 1 |
| Kim, DD | 1 |
| Procyshyn, RM` | 1 |
| Tibbo, P | 1 |
| Greil, W | 1 |
| Häberle, A | 1 |
| Schuhmann, T | 1 |
| Grohmann, R | 1 |
| Baumann, P | 1 |
| López-Rodríguez, R | 1 |
| Cabaleiro, T | 1 |
| Ochoa, D | 1 |
| Román, M | 1 |
| Borobia, AM | 1 |
| Carcas, AJ | 1 |
| Ayuso, C | 2 |
| Novalbos, J | 1 |
| Abad-Santos, F | 2 |
| Ameis, SH | 1 |
| Corbett-Dick, P | 1 |
| Cole, L | 1 |
| Correll, CU | 1 |
| Tsermpini, EE | 1 |
| Assimakopoulos, K | 1 |
| Bartsakoulia, M | 1 |
| Iconomou, G | 1 |
| Papadima, EM | 1 |
| Mitropoulos, K | 1 |
| Squassina, A | 1 |
| Patrinos, GP | 1 |
| de Araújo, AA | 2 |
| Ribeiro, SB | 2 |
| Dos Santos, AC | 1 |
| Lemos, TM | 1 |
| Medeiros, CA | 1 |
| Guerra, GC | 2 |
| de Araújo Júnior, RF | 2 |
| Serrano-Blanco, A | 2 |
| Rubio-Valera, M | 1 |
| Garcia-Amador, M | 1 |
| Merchán-Naranjo, J | 1 |
| Tapia, C | 1 |
| Moreno, C | 1 |
| Castro-Fornieles, J | 1 |
| Baeza, I | 1 |
| de la Serna, E | 1 |
| Alda, JA | 1 |
| Muñoz, D | 1 |
| Andrés Nestares, P | 1 |
| Cantarero, CM | 1 |
| Arango, C | 1 |
| Nikvarz, N | 1 |
| Alaghband-Rad, J | 1 |
| Tehrani-Doost, M | 1 |
| Alimadadi, A | 1 |
| Ghaeli, P | 1 |
| Polcwiartek, C | 1 |
| Vang, T | 1 |
| Bruhn, CH | 1 |
| Hashemi, N | 1 |
| Rosenzweig, M | 1 |
| Nielsen, J | 1 |
| Simon, V | 1 |
| van Winkel, R | 1 |
| De Hert, M | 1 |
| Wittmann, M | 1 |
| Hausner, H | 1 |
| Hajak, G | 1 |
| Haen, E | 1 |
| Singh, D | 1 |
| O'Connor, DW | 1 |
| Klemperer, D | 1 |
| Kane, JM | 1 |
| Potkin, SG | 1 |
| Daniel, DG | 1 |
| Buckley, PF | 1 |
| Almoguera, B | 1 |
| Riveiro-Alvarez, R | 1 |
| Lopez-Castroman, J | 1 |
| Dorado, P | 1 |
| Vaquero-Lorenzo, C | 1 |
| Fernandez-Piqueras, J | 1 |
| Llerena, A | 1 |
| Baca-García, E | 1 |
| Dal-Ré, R | 1 |
| Huybrechts, KF | 1 |
| Gerhard, T | 1 |
| Crystal, S | 1 |
| Olfson, M | 1 |
| Avorn, J | 1 |
| Levin, R | 1 |
| Lucas, JA | 1 |
| Schneeweiss, S | 1 |
| Chaves, KM | 1 |
| Soares, LA | 1 |
| do Socorro Costa Feitosa Alves, M | 1 |
| de Paula Soares Rachetti, V | 1 |
| Filgueira Júnior, A | 1 |
| Parellada, E | 1 |
| Luby, J | 1 |
| Mrakotsky, C | 1 |
| Stalets, MM | 1 |
| Belden, A | 1 |
| Heffelfinger, A | 1 |
| Williams, M | 1 |
| Spitznagel, E | 1 |
| Madhusoodanan, S | 1 |
| Bogunovic, O | 1 |
| Hendset, M | 1 |
| Hermann, M | 1 |
| Kissling, W | 1 |
| Glue, P | 1 |
| Medori, R | 1 |
| Simpson, S | 1 |
| Mackay, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind, Placebo Controlled, Crossover Study of Extended Release Methylphenidate for Treatment of ADHD in Children With Epilepsy[NCT00323947] | Phase 4 | 33 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Metabolic Effects of Antipsychotics in Children[NCT00205699] | Phase 4 | 144 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This study hypothesized that antipsychotic treatment would increase percent total body fat, as measured by whole body dual energy x-ray absorptiometry (DEXA), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | percent body fat (Mean) |
|---|---|
| Risperidone | 1.81 |
| Olanzapine | 4.12 |
| Aripiprazole | 1.66 |
This study hypothesized that antipsychotic treatment would decrease hepatic insulin sensitivity, as measured by the rate of appearance of glucose (glucose Ra), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | percentage of % change (Mean) |
|---|---|
| Risperidone | -2.50 |
| Olanzapine | -6.57 |
| Aripiprazole | -3.27 |
This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at muscle, as measured by the insulin-stimulated rate of disappearance of glucose (glucose Rd), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | percentage of % change (Mean) |
|---|---|
| Risperidone | 2.30 |
| Olanzapine | -29.34 |
| Aripiprazole | -30.26 |
This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at adipose tissue, as measured by the insulin-stimulated rate of disappearance of glycerol (glycerol Ra), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | percentage of % change (Mean) |
|---|---|
| Risperidone | -3.65 |
| Olanzapine | -8.29 |
| Aripiprazole | 1.70 |
This study hypothesized that antipsychotic treatment would increase subcutaneous abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | Change in cm-squared (Mean) |
|---|---|
| Risperidone | 18.21 |
| Olanzapine | 34.27 |
| Aripiprazole | 15.84 |
This study hypothesized that antipsychotic treatment would increase visceral abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | Change in cm-squared (Mean) |
|---|---|
| Risperidone | 6.85 |
| Olanzapine | 10.73 |
| Aripiprazole | 12.04 |
8 reviews available for risperidone and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2022 |
Topics: Adolescent; Antipsychotic Agents; Child; Cytochrome P-450 CYP2D6; Drug-Related Side Effects and Adve | 2021 |
No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment.
Topics: Adult; Aged; Antipsychotic Agents; Body Mass Index; Drug-Related Side Effects and Adverse Reactions; | 2018 |
Individualizing clozapine and risperidone treatment for schizophrenia patients.
Topics: Clozapine; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmacogenetics; Precision Medi | 2014 |
Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Denmark; Diabe | 2016 |
Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Clozapine; Controlled Clinical Trials as Topic; Dose | 2009 |
Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.
Topics: Aged; Antipsychotic Agents; Delayed-Action Preparations; Drug-Related Side Effects and Adverse React | 2009 |
Clinical experience and management considerations with long-acting risperidone.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Drug-Related Sid | 2006 |
6 trials available for risperidone and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study.
Topics: Antipsychotic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Prolactin; Risperidon | 2023 |
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.
Topics: Abdominal Fat; Absorptiometry, Photon; Adolescent; Antipsychotic Agents; Aripiprazole; Child; Drug-R | 2018 |
Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers, Pharmacological; Dibenzothiazepines; Drug- | 2013 |
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug-Related Side Effects and Adv | 2011 |
Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.
Topics: Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child Behavior Disorders; Child, | 2006 |
Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparatio | 2007 |
28 other studies available for risperidone and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cl | 2022 |
Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug | 2022 |
Drug-induced weight gain in the last 10 years: a descriptive study.
Topics: Adalimumab; Adverse Drug Reaction Reporting Systems; Aripiprazole; Databases, Factual; Drug-Related | 2022 |
Recognising side effects of antipsychotics in children with intellectual disabilities.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Drug-Related Side Effects and Adverse Reactio | 2023 |
[Clinical use of psychotropic drugs: A look at antipsychotic drugs].
Topics: Aged; Antipsychotic Agents; Dementia; Drug-Related Side Effects and Adverse Reactions; Humans; Psych | 2023 |
Janssen Pharmaceutica, Long-Acting Risperidone and Public Health Program of India.
Topics: Antipsychotic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; India; Public Health; | 2021 |
Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Drug-Related Side Effects and Adverse Reactions; Fem | 2021 |
Getting to Precision Psychopharmacology in Child Psychiatry: The Value of Adverse Treatment Effects.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Psychiatry; Drug-Related Side Effects and Adverse R | 2021 |
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
Topics: Adolescent; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transp | 2018 |
An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Biomarkers; Child; Child, Preschool; Databases, | 2018 |
An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Biomarkers; Child; Child, Preschool; Databases, | 2018 |
An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Biomarkers; Child; Child, Preschool; Databases, | 2018 |
An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Biomarkers; Child; Child, Preschool; Databases, | 2018 |
Adherence to Antipsychotic Adverse Effect Monitoring Among a Referred Sample of Children with Intellectual Disabilities.
Topics: Adolescent; Antipsychotic Agents; Body Mass Index; Canada; Community Mental Health Services; Drug-Re | 2019 |
Management of sexual adverse effects induced by atypical antipsychotic medication
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug-Related Side Effects and Adverse | 2019 |
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2013 |
Decision making and antipsychotic medication treatment for youth with autism spectrum disorders: applying guidelines in the real world.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child | 2013 |
Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Body Weights and Measures; Cross-Secti | 2016 |
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Drug-Related Side Effect | 2015 |
Comparing Efficacy and Side Effects of Memantine vs. Risperidone in the Treatment of Autistic Disorder.
Topics: Autistic Disorder; Child; Child, Preschool; Dopamine Agents; Dose-Response Relationship, Drug; Drug- | 2017 |
[Antipsychotic treatment of dementia after publication of new risks].
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alzheimer Disease; Antipsychotic Agents; Cerebral Inf | 2010 |
Drug research: marketing before evidence, sales before safety.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Conflict of Interest; Drug Industry | 2010 |
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.
Topics: Alleles; Drug-Related Side Effects and Adverse Reactions; Genetic Association Studies; Humans; Polym | 2013 |
Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cause of Death; Comorbidity; Dementia; Dibenzothiazep | 2012 |
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia.
Topics: Activities of Daily Living; Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Brazil; C | 2013 |
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzodiazepines; Comorbidity; Dementia, Vascular; Dose-R | 2007 |
[Why measure drug metabolites?].
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cyclohexanols; Cytochrome P-450 Enzy | 2007 |
Post-marketing studies: the work of the Drug Safety Research Unit.
Topics: Antipsychotic Agents; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Epidemiol | 1998 |